A Phase 3 Study to investigate the effect of study drug on the reduction of Major Adverse Cardiovascular Events (MACE) in adults with elevated Lipoprotein(a) who have established Atherosclerotic Cardiovascular Disease or are at risk for a first Cardiovascular Event
Criteria:Be 18 years or older
Have established ASCVD - Coronary artery disease; cerebrovascular disease; Peripheral arterial disease
Risk factor first CV event - documented CAD or PAD; known familial hypercholesterolemia; hypertension, kidney disease; diabetes; family history of ASCVD; coronary artery calcium (CAC); hyperlipidemia